Archives

  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • 2025-05
  • 2025-04
  • CCK-8 Ammonium Promotes ANP Secretion via NOX4–PGC-1α–PPAR A

    2026-05-20

    Cholecystokinin Octapeptide Ammonium and ANP Secretion: Mechanistic Insights from Rat Atria

    Study Background and Research Question

    Atrial natriuretic peptide (ANP) is a critical cardiac hormone, primarily released from atrial myocytes in response to mechanical stretch or neurohumoral stimuli. Beyond its established roles in regulating blood pressure and fluid homeostasis, ANP also exerts anti-inflammatory, antihypertrophic, and antioxidant effects in the cardiovascular system. The peptide hormone cholecystokinin (CCK), traditionally recognized for its functions in the gastrointestinal tract, has also been localized in cardiomyocytes, where it participates in diverse regulatory processes. However, the direct mechanistic link between CCK signaling and ANP secretion in the heart had remained unresolved.

    The referenced study (Han et al., 2022) sought to clarify whether sulfated CCK-8—the major active fragment of CCK—can modulate ANP secretion and atrial contractile dynamics, and to delineate the underlying molecular pathways in isolated perfused beating rat atria.

    Key Innovation from the Reference Study

    The central innovation lies in the identification of a signaling cascade in which sulfated cholecystokinin octapeptide (CCK-8 ammonium) triggers ANP secretion through a defined molecular pathway: activation of CCK receptors leads to upregulation of NADPH oxidase 4 (NOX4), which in turn stimulates peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) via p38 MAPK signaling, culminating in the activation of PPARα and PPARγ and subsequent ANP release. This work not only clarifies the direct stimulatory effect of CCK-8 ammonium on ANP secretion, but also connects CCK signaling to antioxidant and metabolic regulatory networks in cardiac tissue (Han et al., 2022).

    Methods and Experimental Design Insights

    The authors employed isolated perfused beating rat atria to enable precise assessment of hormone secretion and contractile function under controlled conditions. Key methodological features included:

    • Administration of sulfated and desulfated CCK-8 peptides to dissect the role of sulfation in biological activity.
    • Quantification of ANP secretion via radioimmunoassay, enabling sensitive detection of peptide release.
    • Measurement of hydrogen peroxide (H2O2) and arachidonic acid (AA) using ELISA kits to probe oxidative and lipid signaling components.
    • Protein and mRNA expression profiling (Western blot, RT-qPCR) for key signaling molecules (NOX4, PGC-1α, PPARs, SOD, CAT).
    • Pharmacological interventions with receptor antagonists and channel blockers to delineate pathway specificity.

    This experimental design allowed for a mechanistic dissection of CCK-8 ammonium’s effects, distinguishing receptor- and sulfation-dependent actions from non-specific peptide signaling.

    Core Findings and Why They Matter

    The study’s pivotal findings can be summarized as follows:

    • Sulfation is critical for activity: Only sulfated CCK-8 (not desulfated) significantly increased ANP secretion and modulated atrial contractility, underscoring the importance of peptide post-translational modification.
    • CCK-8 ammonium activates a NOX4–PGC-1α–PPARα/γ axis: Application of CCK-8 ammonium led to increased NOX4 expression and H2O2 production, which then enhanced PGC-1α and PPARα/γ levels, ultimately driving ANP secretion (Han et al., 2022).
    • Receptor specificity and downstream signaling: The effects were mediated by CCK1R and CCK2R, both classified as G protein-coupled receptors, with downstream involvement of p38 MAPK and serine/threonine kinase pathways.
    • Feedback regulation by ANP: Interestingly, blocking ANP receptors amplified CCK-8-induced AA release and oxidative enzyme expression, while suppressing SOD induction, suggesting a negative feedback loop wherein ANP limits excessive ROS production.
    • Physiological relevance: The findings bridge gut-brain peptides and cardiac hormone signaling, providing a foundation for investigating CCK-8 ammonium in disorders of cardiac function, redox balance, and fluid regulation.

    These results collectively highlight CCK-8 ammonium’s role not only as a hormone modulator but also as a context-dependent regulator of cardiac metabolism and oxidative defense—implicating it in broader physiological and pathophysiological states.

    Comparison with Existing Internal Articles

    Several recent reviews and experimental reports have considered the pleiotropic effects of cholecystokinin octapeptide ammonium (CCK-8 ammonium) in neurobehavioral, immunological, and cardiovascular contexts. For instance, the synthesis at CCK-8 Assay highlights the versatility of CCK-8 ammonium as a G protein-coupled receptor ligand, with mechanistic emphasis on the same NOX4–PGC-1α–PPAR axis validated by the present reference study. Similarly, a translational overview at GTP Solution discusses the compound’s capacity to directly stimulate ANP secretion and its broader implications for cardiovascular signaling research. Both sources corroborate the referenced study’s assertion that sulfation and receptor specificity are essential for biological activity, and they elaborate on the peptide’s context-dependent effects, including modulation of immune responses and inhibition of apoptosis in neuronal cells.

    However, the current reference uniquely delineates the direct sequence of molecular events—particularly the integration of ROS (NOX4-derived H2O2), metabolic coactivators (PGC-1α), and nuclear receptors (PPARα/γ)—in the context of live beating atrial tissue, providing a higher level of mechanistic resolution than prior summaries or protocol-focused discussions.

    Limitations and Transferability

    While the study offers compelling mechanistic evidence, there are inherent limitations to consider:

    • Species and system specificity: The experiments were conducted in isolated rat atrial preparations, which, while physiologically relevant, may not fully capture the complexities of in vivo systemic regulation or human cardiac physiology.
    • Pharmacological concentrations: The concentrations of CCK-8 ammonium used (0.01–1 μmol/L) are within established experimental ranges, but extrapolation to pathophysiological or therapeutic scenarios requires caution.
    • Context dependence: The observed effects are tightly linked to peptide sulfation status and receptor subtype expression, which may vary across tissues, developmental stages, or disease states.
    • Downstream consequences: While the study establishes a clear pathway for ANP secretion, longer-term effects on cardiac function, remodeling, or systemic homeostasis were not addressed directly.

    Therefore, while the data robustly support the role of CCK-8 ammonium in ANP regulation via the NOX4–PGC-1α–PPAR axis, further research is needed to define its translational potential and applicability in complex models or clinical settings.

    Protocol Parameters

    • CCK-8 ammonium effective concentrations: Experimental evidence supports use of 0.01–1 μmol/L in vitro and 1–10 pmol/g body weight in vivo for studying receptor-mediated signaling (product information).
    • Sulfation requirement: Only sulfated CCK-8 (not desulfated forms) is active in promoting ANP secretion according to the reference study.
    • Receptor targeting: Both CCK1R and CCK2R agonism are implicated, suggesting that selective antagonists can be used to dissect pathway contributions.
    • Oxidative stress markers: Include measurement of H2O2, AA, SOD, CAT, and NOX4 expression to monitor pathway activation.
    • Peptide handling: CCK-8 ammonium is insoluble in DMSO, ethanol, and water; dissolve and store according to manufacturer recommendations (–20°C, nitrogen, dry, light-protected).

    Research Support Resources

    For researchers aiming to replicate or extend these findings, Cholecystokinin octapeptide ammonium (SKU C8717) is available in a standardized, sulfated form suitable for use in signaling pathway and peptide secretion studies. Additional mechanistic background, translational perspectives, and protocol guidance can be found in the internal reviews linked above. As always, attention to peptide sulfation status, receptor subtype specificity, and concentration parameters is essential for experimental reproducibility and accurate interpretation.